Gabriel Horta-Baas1, Antonio Sandoval-Cabrera2,3, María Del Socorro Romero-Figueroa3,4. 1. Servicio de Reumatología, Hospital General Regional número 1, Delegación Yucatán, Instituto Mexicano del Seguro Social, Calle 41 No. 439 x 34. Colonia Industrial, 97150, Mérida, Yucatán, Mexico. gabho@hotmail.com. 2. Laboratorio de alta especialidad en Hemato-Oncología, Hospital para el Niño, IMIEM, Toluca, Mexico. 3. Facultad de Medicina, Campus Universitario Siglo XXl, Zinacantepec, State of Mexico, Mexico. 4. Centro de Investigación en Ciencias de la Salud, Campus Norte Huixquilucan, Universidad Anáhuac México, Mexico City, Mexico.
Abstract
PURPOSE OF REVIEW: This Review evaluates the available information on the modification of the microbiota by diet, prebiotics, probiotics, or drugs and its association with the severity of arthritis in animals and humans and highlights how this modulation could have therapeutic applications in RA. RECENT FINDINGS: The gut microbiota and microbiota-derived metabolites play a role in developing rheumatoid arthritis (RA) in animals and humans, making the intestinal microbiota an exciting novel approach to suppress autoimmunity. Studies in animal models of RA show that it is possible to modify the intestinal microbiota with drugs, natural products, diet, probiotics, and prebiotics. Furthermore, these changes showed beneficial effects on symptom relief in animal models of RA and that these effects were associated with modulation of the immune response. Therapies that modify the gut microbiota would significantly impact the preclinical stage of arthritis, based on the fact that dysbiosis occurs before clinical arthritis. The effects of interventions to modulate the microbiota could not reverse arthritis. Furthermore, the therapies modulating therapies in controlling symptoms were limited once arthritis developed. The results obtained in the study of acarbose, probiotics, and prebiotics suggest that these interventions may decrease the disease's incidence rather than treat or cure it.
PURPOSE OF REVIEW: This Review evaluates the available information on the modification of the microbiota by diet, prebiotics, probiotics, or drugs and its association with the severity of arthritis in animals and humans and highlights how this modulation could have therapeutic applications in RA. RECENT FINDINGS: The gut microbiota and microbiota-derived metabolites play a role in developing rheumatoid arthritis (RA) in animals and humans, making the intestinal microbiota an exciting novel approach to suppress autoimmunity. Studies in animal models of RA show that it is possible to modify the intestinal microbiota with drugs, natural products, diet, probiotics, and prebiotics. Furthermore, these changes showed beneficial effects on symptom relief in animal models of RA and that these effects were associated with modulation of the immune response. Therapies that modify the gut microbiota would significantly impact the preclinical stage of arthritis, based on the fact that dysbiosis occurs before clinical arthritis. The effects of interventions to modulate the microbiota could not reverse arthritis. Furthermore, the therapies modulating therapies in controlling symptoms were limited once arthritis developed. The results obtained in the study of acarbose, probiotics, and prebiotics suggest that these interventions may decrease the disease's incidence rather than treat or cure it.
Entities:
Keywords:
Gut microbiome; Gut microflora; Rheumatic diseases; Rheumatoid arthritis
Authors: Paul I Costea; Falk Hildebrand; Manimozhiyan Arumugam; Fredrik Bäckhed; Martin J Blaser; Frederic D Bushman; Willem M de Vos; S Dusko Ehrlich; Claire M Fraser; Masahira Hattori; Curtis Huttenhower; Ian B Jeffery; Dan Knights; James D Lewis; Ruth E Ley; Howard Ochman; Paul W O'Toole; Christopher Quince; David A Relman; Fergus Shanahan; Shinichi Sunagawa; Jun Wang; George M Weinstock; Gary D Wu; Georg Zeller; Liping Zhao; Jeroen Raes; Rob Knight; Peer Bork Journal: Nat Microbiol Date: 2017-12-18 Impact factor: 17.745
Authors: Gabriel Horta-Baas; María Del Socorro Romero-Figueroa; Alvaro José Montiel-Jarquín; María Luisa Pizano-Zárate; Jaime García-Mena; Ninfa Ramírez-Durán Journal: J Immunol Res Date: 2017-08-30 Impact factor: 4.818
Authors: Rebecca Rogier; Heather Evans-Marin; Julia Manasson; Peter M van der Kraan; Birgitte Walgreen; Monique M Helsen; Liduine A van den Bersselaar; Fons A van de Loo; Peter L van Lent; Steven B Abramson; Wim B van den Berg; Marije I Koenders; Jose U Scher; Shahla Abdollahi-Roodsaz Journal: Sci Rep Date: 2017-11-15 Impact factor: 4.379
Authors: Rebecca Rogier; Thomas H A Ederveen; Harm Wopereis; Anita Hartog; Jos Boekhorst; Sacha A F T van Hijum; Jan Knol; Johan Garssen; Birgitte Walgreen; Monique M Helsen; Peter M van der Kraan; Peter L E M van Lent; Fons A J van de Loo; Shahla Abdollahi-Roodsaz; Marije I Koenders Journal: PLoS One Date: 2019-07-08 Impact factor: 3.240
Authors: Luis Fernando Méndez-López; Deisy Sosa de León; Manuel López-Cabanillas Lomelí; Blanca Edelia González-Martínez; Jesús Alberto Vázquez-Rodríguez Journal: Front Nutr Date: 2022-03-04